Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials

•The adverse event (AE) profile of extended-release niacin-laropiprant (ERN-LRPT) 2 g was examined.•Data from 12 clinical studies (12–52 weeks; N = 11,310 patients) were pooled.•Except for reduced flushing, the AE profile of ERN-LRPT was similar to ERN 2 g alone.•AEs were mostly nonserious and typical of ERN (gastrointestinal, increased glucose).•LRPT did not appear to adversely affect the AE profile of ERN.